CA-AIRSPACE
Airspace today announced it has been granted a U.S. patent for its optimized logistics management system as of March 2. The patent covers the system, method, and computer programming of the logistical and graphical presentation of the most optimal path for transporting goods from a pickup location to a destination location at lowest transit cost and minimal risk.
Airspace leverages its patented technology and world-class team to provide certainty in the time-critical logistics space through unrivaled speed and shipment transparency . The routing operation is arguably the most important step in the logistical transportation process because the optimal route saves both money and time, while enabling customers to monitor progress along the route provides transparency.
“This technology is a game-changer for the supply chain and logistics industry,” said Ryan Rusnak , co-founder and CTO at Airspace.
Airspace’s technology calculates the best routes in less than a second instead of the typical 30 minutes or more that are standard in the time-critical shipping industry. The router generates a time and space expectation of where each order should be at any given time, which is checked via distributed sensors. Even if an expected flight is canceled, the technology immediately establishes a new plan and tracks it. Airspace provides automated notifications in real time to the customer instead of having to wait for personal contact calls, generating leading indicators rather than lagging ones.
“Our transparency with this process creates trust and confidence for both shippers and receivers,” said Rusnak. “We believe we are setting a new standard for the logistics industry.”
Logistical challenges are difficult because most shipments don’t start at an airport; they start at an arbitrary place such as a lab, warehouse, hospital, and so on. Airspace’s technology takes into consideration ground travel time as well, allowing for traffic to and from nearby airports to the final destination. This technology can provide the difference between life and death, for example, in the case of organs for transplant.
“If you choose a route that doesn’t give the driver enough time, you set the shipment up for failure. Create a route that is too conservative, and you risk losing the last flight that gets the package there when it’s needed,” said Nick Bulcao , co-founder and CEO of Airspace. “This is the extremely difficult optimization challenge that only Airspace can solve today, using our proprietary software and artificial intelligence. We are extremely proud of our inventors and pleased that our technology can make a real difference.”
Airspace, which recently closed its Series C funding round , is positioned to provide the best customer experience for clients while relentlessly analyzing data to address ongoing needs. It continues to grow, focused on making international expansion as seamless as possible by blending operations and R&D for the benefit of the industry.
About Airspace
Airspace, founded in 2016, has grown to be a leading global delivery network for time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through its people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints, Airspace surfaces more information than any other provider, increasing trust and transparency of the supply chain. To learn more, visit www.airspace.com . Follow Airspace: Twitter , Facebook , Instagram and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005325/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
